Prognostic Values of Long Noncoding RNA GAS5 in Various Carcinomas: An Updated Systematic Review and Meta-Analysis

Qunjun Gao1,2†, Haibiao Xie1,3†, Hengji Zhan1,4†, Jianfa Li1†, Yuchen Liu1* and Weiren Huang1*

† Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Graduate School of Guangzhou Medical University, Shenzhen, China, 2 Guangzhou Medical University, Guangzhou, China, 3 Shantou University Medical College, Shantou, China, 4 Shenzhen University, Shenzhen, China

The growth arrest-specific transcript 5 (GAS5) is a long noncoding RNA with low expression in multiple cancers. This meta-analysis aims to explore the association between GAS5 expression levels and cancer patients’ prognosis. We collected all the relevant literatures about GAS5 expression levels associated with overall survival (OS), lymph node metastasis (LNM) and high tumor stage (II/III/IV) (HTS) from the PubMed and Web of Science. The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were calculated to evaluate the link strength between GAS5 and cancer prognosis. A total of 934 patients from 14 studies were included to the present meta-analysis, according to the inclusion and exclusion criteria. The results demonstrated that low expression of GAS5 could predict poor OS in cancer patients (HR = 1.955, 95% CI: 1.551–2.465, \( P < 0.001 \)). Meanwhile we also analyzed the following cancers independently: hepatocellular carcinoma (HR = 1.893, 95% CI: 1.103–3.249, \( P = 0.021 \)) and urothelial carcinoma (HR = 1.653, 95% CI: 1.185–2.306, \( P = 0.003 \)). Compared to the high GAS5 expression group, additionally, patients with low GAS5 expression in tumor tissues were more prone to lymph node metastasis (OR = 0.234, 95% CI: 0.153–0.358, \( P < 0.001 \)) and high tumor stage (OR = 0.185, 95% CI: 0.102–0.333, \( P < 0.001 \)). In conclusion, this meta-analysis showed that GAS5 might be served as a novel biomarker for predicting prognosis in various types of cancers.

Keywords: lncRNA, GAS5, cancer, prognosis, lymph node metastasis, high tumor stage, meta-analysis

INTRODUCTION

Cancer has become a global health problem. In recent years, the incidence of cancer has been increased year by year. According to WHO estimates, 14.1 million new cancer patients and 8.2 million deaths from cancer occurred worldwide in 2012 and more than 20 million new cases of cancer will be expected as early as 2025 (Ferlay et al., 2015). At present, cancer treatment includes surgery, radiotherapy, chemotherapy and etc., but the 5 years survival rate is still not ideal, especially some patients with lymph node metastasis or high stage tumor (Saika and Sobue, 2013). Therefore, it is important to find a new biological target that plays a guiding role in the carcinogenesis to detect cancer. It is also more conducive to early detection, early diagnosis and early treatment of tumor patients.
Long non-coding RNAs (lncRNAs) are non-coding RNAs with a length of more than 200 nucleotides that regulate gene expression (Mattick and Makunin, 2006). They were described as “noise,” and did not attract much attention in the past few decades (Ponjavic et al., 2007). With the application of whole genome sequencing and microarray, lncRNAs have attracted more and more attentions (Batista and Chang, 2013; Tang et al., 2013). The increasing evidence show that lncRNAs play a pivotal role in the development and progression of tumors, which means that they can be used as biomarkers for some tumors (Fang et al., 2017; Liu et al., 2017; Sun et al., 2017; Yang et al., 2017). However, only a few number of lncRNAs have corresponding functional features, and most of the functions of lncRNAs remain unclear.

The growth arrest-specific transcript 5 (GAS5) is a rising star among tumor-suppressive lncRNAs among all the kinds of lncRNAs (Ma et al., 2016). Recent studies have shown that GAS5 plays a key role in a variety of human diseases and participates in a variety of biological processes, such as cell proliferation, cell apoptosis, epithelial-mesenchymal transition and etc. (Tan et al., 2017; Tao et al., 2017; Wen et al., 2017; Yang et al., 2017). Meanwhile, GAS5 is also involved in the progression of many types of cancer, such as bladder cancer (BC) (Zhang et al., 2017), colorectal cancer (CRC) (Yin et al., 2014; Li et al., 2017), non-small cell lung cancer (NSCLC) (Shi et al., 2015; Wu et al., 2016), breast cancer (BRC) (Li W. et al., 2016), hepatocellular carcinoma (HCC) (Tu et al., 2014; Chang et al., 2016; Hu et al., 2016), epithelial ovarian cancer (EOC) (Gao et al., 2015), gastric cancer (GC) (Sun et al., 2014), cervical cancer (CEC) (Cao et al., 2014), and head and neck squamous cell carcinoma (HNSCC) (Gee et al., 2011). The clinic pathological features of the patients, such as overall survival (OS), lymph node metastasis (LNM) and high tumor stage (II/III/IV) (HTS), are also highly correlated with the level of GAS5 expression in these cancers (Gee et al., 2011; Cao et al., 2014; Sun et al., 2014; Tu et al., 2014; Yin et al., 2014; Gao et al., 2015; Shi et al., 2015; Chang et al., 2016; Hu et al., 2016; Li J. et al., 2016; Wu et al., 2016; Droop et al., 2017; Li et al., 2017; Zhang et al., 2017). All these indicate that GAS5 can be a novel prognostic biomarker in unique cancer. To shed light on the relationship between GAS5 and cancer prognosis, the meta-analysis on the association between the expression of GAS5 and the prognosis of cancer is required. Although a meta-analysis has reported that the expression of GAS5 predicts poorer survival outcomes, only 4 literatures have been included in that work and the results may be incidental (Song et al., 2016). To verify the accuracy of the previous results, the present meta-analysis with 14 studies may provide a more accurate conclusion.

**MATERIALS AND METHODS**

**Literature Collection**

We searched potentially eligible literatures through PubMed, Web of Science to locate articles (published during March 2011 to April 2017), including articles referenced in the publications. We used “GAS5 or growth arrest specific 5” AND “cancer or tumor or carcinomas or neoplasm” as the keywords, in order to identify potentially relevant studies. Citation lists of retrieved articles were searched manually to ensure sensitivity of the search strategy.

**Inclusion and Exclusion Criteria**

All the eligible study data elements were independently assessed and extracted by two investigators. For inclusion in this meta-analysis, the studies met the following criteria: the association between GAS5 and cancer prognosis (OS) was investigated; patients were grouped according to the expression levels of GAS5; related clinic pathologic parameters were described, such as LNM, TNM and sufficient original data for calculating a hazard ratio (HR) with its 95% confidence interval (CI). Exclusion criteria are as the following: Duplicate publications; irrelevant to cancer, GAS5, or cancer prognosis; animal studies, letters, editorials, expert opinions, abstracts, case reports and reviews; studies without usable data.

**Data Extraction**

According to the inclusion and exclusion criteria, two investigators extracted and reviewed the data independently (GQJ, XHB), and disagreements were discussed with two investigators (ZHJ, LYC) in conference. The following data were extracted: first author, publication date, country of origin, tumor type, total number of patients, number of high GAS5 expression group and low GAS5 expression group, number of patients with LNM, number of patients with HTS, detection method of GAS5 expression levels, follow-up month and cut-off values, multivariate analysis, hazard ratios (HRs), and corresponding 95% CI for OS.

**Statistical Methods**

Meta-analysis was performed using Stata12.0 software. Pooled hazard ratios (HRs) were extracted from the included studies; the log HR and standard error (SE) were used for aggregation of the survival results (Tierney et al., 2007). To determine the heterogeneity among the included studies, chi-square-based Q test and I² statistics were used (Higgins et al., 2003). If the $P < 0.1$ or $I^2 > 50\%$, it means that significant heterogeneity existed among the included studies, thus the random-effects model was adopted to analyze the results. The fixed-effects model was applied when between-study heterogeneity was absent ($P > 0.1$ and $I^2 < 50\%$). The potential publication bias was assessed using the Egg's test and $P < 0.05$ was considered representative of statistically significant publication bias. Sensitivity analysis was performed by sequential omission of each individual study in order to validate the stability of outcomes in the present meta-analysis.

**Quality Assessment of Primary Studies**

Two investigators (GQJ, XHB) performed the quality assessment of primary studies independently. We evaluated all eligible studies’ quality by using the Newcastle-Ottawa Scale (NOS) for assessing the quality of studies in meta-analyses (Zeng et al., 2015). The higher scores indicated better methodological quality.

**RESULTS**

**Characteristics and Eligible Studies**

The initial search of the electronic database retrieved 137 literatures. After removing the duplicates, 104 articles were remained. Then we carefully screened the title and abstract, 25
literatures were excluded because the studies were irrelevant. Upon further review of the full articles, the articles with no survival outcomes, lymph node metastasis, TNM stage, animal testing and other factors were excluded. 14 articles were eventually selected for the present meta-analysis (Figure 1). A total of 934 patients were included among these studies, with a maximum sample size of 106 and a minimum sample size of 24 patients (Mean 67). The publication years of the included studies were between 2011 and 2017. In these studies, one was from UK, one was from Germany and 8 were from China. A total of 9 different types of cancer were evaluated in studies of this meta-analysis (3 hepatocellular carcinoma, 2 colorectal cancer, 2 non-small cell lung cancer, 2 urothelial carcinoma, 1 breast cancer, 1 epithelial ovarian cancer, 1 gastric cancer, 1 cervical cancer and 1 head and neck squamous cell carcinoma). The expression of GAS5 was detected by qRT-PCR and the cut-off values included in the studies were inconsistent. All diagnoses of LNM and TNM were based on pathology. Hazard ratios with the corresponding 95% CIs were extracted from the graphical survival plots and the articles. The main characteristics of the eligible studies were summarized in Table 1. The Newcastle-Ottawa Scale (NOS) confirmed that all the studies were of high quality (Table 2).

**Meta-Analysis Result**

**Association between GAS5 and OS in Seven Types of Cancers**

Among the included studies, 10 reported the overall survival (OS) of 730 patients according to GAS5 expression levels. In order to study the relationship between GAS5 expression level and prognosis, the fixed-effect model was used to calculate the pooled HR with corresponding 95% CI because heterogeneity analysis showed that low between-study heterogeneity among those nine studies for GAS5 expression was found ($I^2 = 0.0\%$, $P(H) = 0.728$). We found an inverse relationship that low expression of GAS5 might be associated with poor overall survival outcome ($HR = 1.955$, 95% CI:1.551–2.465, $P < 0.001$, fixed-effect model) (Figure 2). In a subgroup analysis of cancer sites, we also found the similar significant adverse association between levels of GAS5 and OS in the following cancers (low/high): HCC ($HR = 1.893$, 95% CI: 1.103–3.249, $P = 0.021$, $P(H) = 0.902$), UC ($HR = 1.653$, 95% CI: 1.185–2.306, $P = 0.003$, $P(H) = 0.268$) and HR for the subgroup of other cancers was 2.641 (95%CI: 1.625–4.204, $P < 0.001$, $P(H) = 0.730$). We didn’t perform subgroup analyses for CRC, BRC, EOC, GC, CEC, and HNSCC, because there is only one paper investigating these associations between GAS5 and OS (Figure 2) in each cancer type. Compared with the high
| Study | Year | Country | Cancer type | Total number | Detection method | Cut-off | GASS expression | Survival analysis | Multivariate analysis | HR Statistic (95% CI) | Hazard Ratio (L/H) | Follow-up months |
|-------|------|---------|-------------|--------------|-----------------|---------|-----------------|-------------------|---------------------|---------------------|----------------|-----------------|
| Zhang 2016 China | BC | 82 | qRT-PCR | Median | 41 | NA | NA | 41 | NA | NA | OS | Yes | Rep | 2.073 (1.231–3.490) | 60 (Total) |
| Li 2017 China | CRC | 24 | qRT-PCR | Median | 12 | NA | 3 | 12 | NA | 9 | NA | NA | NA | NA | (0.917–2.179) |
| Droop 2017 Germany | UC | 106 | qRT-PCR | Median | 53 | NA | NA | 53 | NA | NA | OS | Yes | Rep | 1.414 | (0.08–5.47) |
| Wu 2016 China | NSCLC | 48 | qRT-PCR | X-tile algorithm | 9 | 3 | 2 | 39 | 27 | 25 | NA | NA | NA | NA | (0.73–5.92) |
| Li 2016 China | BRC | 86 | qRT-PCR | X-tile algorithm | 15 | NA | NA | 71 | NA | NA | OS | Yes | SC | 2.08 (0.70–6.44) | 60 (Total) |
| Hu 2015 China | HCC | 32 | qRT-PCR | X-tile algorithm | 11 | NA | NA | 21 | NA | NA | OS | Yes | SC | 2.08 (0.70–6.44) | 60 (Total) |
| Chang 2015 China | HCC | 50 | qRT-PCR | Mean | 25 | NA | NA | 25 | NA | NA | OS | Yes | SC | 1.96 (0.96–4.00) | 60 (Total) |
| Shi 2015 China | NSCLC | 72 | qRT-PCR | X-tile algorithm | 26 | 13 | 11 | 46 | 36 | 22 | NA | NA | NA | NA | (0.51–1.045) |
| Gao 2015 China | EOC | 60 | qRT-PCR | X-tile algorithm | 29 | 16 | 12 | 31 | 29 | 28 | NA | NA | NA | NA | (0.57–5.49) |
| Yin 2014 China | CRC | 66 | qRT-PCR | Mean | 33 | 24 | 14 | 33 | 32 | 20 | OS | Yes | SC | 2.31 (4.51–10.45) | 60 (Total) |
| Tu 2014 China | HCC | 71 | qRT-PCR | Mean | 20 | NA | 4 | 51 | NA | 28 | OS | Yes | SC | 1.43 (1.02–5.49) | 60 (Total) |
| Sun 2014 China | GC | 89 | qRT-PCR | Mean | 45 | 29 | NA | 44 | 39 | NA | OS | Yes | Rep | 2.46 (1.42–4.26) | 40 (Total) |
| Cao 2014 China | CEC | 102 | qRT-PCR | Median | 58 | NA | 12 | 44 | NA | 32 | OS | Yes | Rep | 3.21 (1.684–6.964) | 44 (Mean) |
| Gee 2011 UK | HNSCC | 46 | qRT-PCR | Median | 23 | NA | 23 | NA | NA | OS | NA | SC | 2.40 (0.31–18.72) | 60 (Total) |

BC: bladder cancer; CRC: colorectal cancer; UC: urothelial carcinoma; NSCLC: non-small cell lung cancer; BRC: breast cancer; HCC: hepatocellular carcinoma; EOC: epithelial ovarian cancer; GC: gastric cancer; CEC: cervical cancer; HNSCC: head and neck squamous cell carcinoma; UK: United Kingdom of Great Britain and Northern Ireland; HTS: high tumor stage (II/III/IV); LNM: lymph node metastasis; DM: distant metastasis; qRT-PCR: quantitative real-time polymerase chain reaction; OS: overall survival; NA: not available; Rep: reported; SC: survival curve; L/H: low expression of GASS/high expression of GASS.
expression group, the low GAS5 expression group indicates a poorer OS which was confirmed statistically significant.

Association between GAS5 and LNM
Based on the differential expression levels of GAS5, seven studies reported 443 patients with lymph node metastasis. Because of the significant between-study heterogeneity ($I^2 = 59.6\%$, $p = 0.021$), the random-effects model was adopted to calculate the odds ratio (high GAS5 expression group vs. low GAS5 expression group; OR = 0.234, 95% CI: 0.153–0.358, $P < 0.001$). It demonstrated that patients with low GAS5 expression in tumor tissues were more prone to lymph node metastasis (Figure 3). In a subgroup analysis of cancer sites, we found the similar outcomes in CRC (OR = 0.353, 95% CI: 0.151–0.831, $P = 0.017$). OR for the subgroup of other cancers was 0.115 (95% CI: 0.06–0.221, $P < 0.001$). But the expression of GAS5 in NSCLC tumor tissues might not be a direct evidence of LNM (OR = 0.516, 95% CI: 0.229–1.164, $P = 0.111$). We didn’t perform subgroup analyses for UC, BRC, HCC, EOC, GC, CEC, and HNSCC, there is only one paper investigating these associations between GAS5 and LNM (Figure 3) in each cancer type.

Association between GAS5 and HTS
Five studies reported the HTS of 335 patients based on various GAS5 expression levels. The fixed-effect model was adopted because there was no heterogeneity ($I^2 = 0.0\%$, $p = 0.966$). The results showed that low GAS5 expression group indicates a poorer OS which was confirmed statistically significant. (Figure 2).
The odds ratio, expressed as high GAS5 expression group vs. low GAS5 expression group, was 0.185 (95% CI: 0.102–0.333, \( P < 0.001 \)). The result showed that patients with low GAS5 expression in cancerous tissues were more prone to high tumor stage (Figure 4). All the results were listed in the Table 3.

**DISCUSSION**

GAS5 has been reported to be down-regulated in multiple cancers, leading to changes in tumor cell production, proliferation, apoptosis, metastasis, and survival time (Chang et al., 2016; Hu et al., 2016; Zhang et al., 2017). In our meta-analysis, we explored the relationship between the level of GAS5 expression and cancer prognostic parameters. The results demonstrated that low expression levels of GAS5 predicted poor OS in various cancers and patients with low GAS5 expression in tumor tissues were more prone to lymph node metastasis.

**Sensitivity Analysis and Publication Bias**

To test the stability of the results of GAS5 and OS, we performed sensitivity analyses by sequentially removing each eligible study and the result was not significantly affected (Figure 5). We also performed a sensitivity analysis of lymph node metastasis and GAS5, and got similar results (Figure 5). We used Egg's test to evaluate potential publication biases of the GAS5 and OS, and the result did not display obvious publication bias for the HR evaluations of OS (\( p = 0.996 \)) (Figure 6).
Meanwhile, we found patients with low GAS5 expression in cancerous tissues were more prone to high tumor stage. Our results showed that low expression levels of GAS5 could be a molecular biomarker of poor prognosis in cancer patients.

As shown in Figure 2, GAS5 and OS are positively related in OS analysis without heterogeneity and publication bias: the low expression of GAS5 predicts poorer survival outcomes. To investigate whether the above analysis was applicable in separate cancers, we made a subgroup analysis. The results was HCC (HR = 1.893, 95% CI: 1.103–3.249, P = 0.021, P(H) = 0.902), UC (HR = 1.653, 95% CI: 1.185–2.306, P = 0.003, P(H) = 0.268) which meant that the above conclusions applied equally in HCC and UC. Meanwhile, we investigated the association between the GAS5 expression levels and LNM and HTS, and we found that low GAS5 expression in cancerous tissues were more prone to LNM and HTS (Figures 3, 4). However, in LNM analysis we found that the included studies existed significantly heterogeneity. So we performed a subgroup analysis according to tumor type, and the results showed that the heterogeneity disappeared obviously in CRC (P for heterogeneity = 0.211, I² = 36.1%, random-effects model), and other types of cancer (P for heterogeneity = 0.516, I² = 0.0%, random-effects model), while the heterogeneity still existed in NSCLC (P for heterogeneity = 0.107, I² = 61.6%, random-effects model) which might be caused by the different cut-off value methods which were adopted to define the high GAS5 expression group or low GAS5 expression group. In conclusion, all these results provided strong evidence for GAS5 as a potential biomarker for the prognosis of various cancers.

Nowadays, many lncRNAs have been found to be abnormally expressed in cancer. Therefore, many meta-analysis articles, like our study, have been used to reveal the correlation of lncRNAs and cancer prognosis. Several lines of studies, meanwhile, have revealed that a lot of lncRNAs play an important role in cancer prognosis, such as TUG1, SPRY4, MALAT1 (Wang et al., 2015, 2017; Yu et al., 2017). For instance, Wang et al. found that SPRY4 is remarkably upregulated in various cancer. Thus, they performed the meta-analysis to examine the association between the SPRY4-IT1 expression level and prognosis in cancer patients. Finally, they suggested the prognostic role of SPRY4-IT1 in human cancers, and increased SPRY4-IT1 expression was closely associated with advanced features of human cancers (Wang et al., 2017). Likewise, NEAT1, as a novel lncRNA, has been recently found to be up-regulated in several cancers, contributing to tumor proliferation, apoptosis, metastasis and survival. Chen et al. conduct a meta-analysis to clarify the association between high NEAT1 expression and poor prognosis. Eventually, they concluded that NEAT1 may serve as a molecular marker and a prognostic factor for patients with various cancers (Chen et al., 2017). Additionally, among these studies, it can be found that

---

TABLE 3 | Results of this meta-analysis.

| Outcome | No. of studies | No. of patients | HR/OR(95%CI) | P | Heterogeneity |
|---------|----------------|----------------|--------------|----|---------------|
|         |                |                |              |    |               |
| OS      | 10             | 730            | 1.955(1.551–2.465) | <0.001 | 0.0 0.728    |
| HCC     | 3              | 153            | 1.893(1.103–3.249) | 0.021 | 0.0 0.902    |
| UC      | 2              | 188            | 1.653(1.185–2.306) | 0.003 | 18.4 0.268   |
| Others  | 5              | 389            | 2.641(1.625–4.204) | <0.001 | 0.0 0.730    |
| LNM     | 7              | 443            | 0.234(0.153–0.358) | <0.001 | 59.6 0.021   |
| CRC     | 2              | 90             | 0.353(0.151–0.831) | 0.017 | 36.1 0.211   |
| NSCLC   | 2              | 120            | 0.516(0.229–1.164) | 0.111 | 61.6 0.107   |
| Others  | 3              | 233            | 0.115(0.06–0.221) | <0.001 | 0.0 0.516    |
| HTS     | 5              | 335            | 0.186(0.102–0.333) | <0.001 | 0.0 0.691    |

OS, overall survival; LNM, lymph node metastasis; HTS, high tumor stage (II/III/IV); HCC, hepatocellular carcinoma; UC, urothelial carcinoma; CRC, colorectal cancer; NSCLC, non-small cell lung cancer; Others, other cancer types; HR, hazard ratios; OR, odds ratios; No, number; CI, confidence interval.

---

FIGURE 5 | Sensitivity analysis of OS and LNM. (A) Sensitivity analysis of effect of individual studies on the pooled HRs for GAS5 and overall survival of patients. (B) Sensitivity analysis of effect of individual studies on ORs for GAS5 and lymph node metastasis of patients.
different lncRNA has specific signaling pathways in cancers. They move the extracellular signaling molecules into the cell and then, in some way, further affect cell phenotypic changes, such as cell metabolism, proliferation, invasion, apoptosis, and so on (Wang et al., 2015, 2017; Yu et al., 2017). To further investigate the value of GAS5, we analyzed and screened the signaling pathways and

---

**TABLE 4 | Summary of GAS5 with their potential targets, pathways and related microRNAs entered.**

| Potential targets | Pathways | Related microRNAs | References |
|------------------|----------|-------------------|------------|
| NA               | Cell proliferation, invasion | miR-135b | Xue et al., 2017 |
| NA               | Cell proliferation, migration, invasion | miR-21 | Hu et al., 2016; Li J. et al., 2016; Wen et al., 2017 |
| NA               | Cell proliferation, invasion and apoptosis | miR-23a | Mei et al., 2017 |
| p53, BRCA1, GADD45A | Cell proliferation | NA | Mazar et al., 2017 |
| P27kip1 | Cell proliferation | NA | Luo et al., 2017 |
| IL-10, VEGF-A | NF-kappaB and Erk1/2 pathways | NA | Li et al., 2017 |
| NA               | Cell proliferation, migration and invasion | miR-137 | Bian et al., 2017 |
| mTOR             | AKT/mTOR signaling pathway | miR-103 | Xue et al., 2016 |
| MT2A             | NA | miR-23a | Liu et al., 2016 |
| P53              | P53 tumor suppressor pathway | NA | Shi et al., 2015; Li T. et al., 2016 |
| D1, p21, APAF1   | Cell proliferation | NA | Li J. et al., 2016 |
| CCL1             | Cell proliferation | NA | Cao et al., 2016 |
| Bcl-2-modifying factor (bmf) and Plexin C1 | cell migration, invasion | miR-222 | Zhao et al., 2015 |
| YBX1             | p21 pathway | NA | Liu et al., 2015 |
| PTEN             | Cell apoptosis | miR-103 | Guo et al., 2015 |
| BAX, BAK, cleaved-caspase 3, cleaved-caspase 9 | Cell proliferation, migration and invasion | NA | Gao et al., 2015 |
| IGF-1R           | EGFR pathway | NA | Dong et al., 2015 |
| E2F1,P21         | Cell proliferation | NA | Sun et al., 2014 |
| PI3K/mTOR        | Cell apoptosis, PI3K/mTOR pathway | NA | Pickard and Williams, 2014; Renganathan et al., 2014 |
| CDK6             | Cell proliferation | NA | Liu et al., 2013 |

NA, not available.
mechanisms of action from all GAS5 related literatures, which will be useful for future studies on tumorigenesis (Table 4).

There are several limitations in our study that should be acknowledged. Firstly, the present study used the summary data rather than a specific patient data. Secondly, the methods for distinguishing the cut-off value of GAS5 in high and low expression groups were inconsonant which inevitably could cause heterogeneity. Thirdly, most of the HR values were not directly reported in these included studies. We extracted and calculated them according to the survival curves, so inevitably there might be errors. Fourthly, different treatment methods for different types of cancer patients after surgery might have great influence on the survival time, which led to the heterogeneity of the researches. Fifthly, we only included English related literatures that could not be so comprehensive. Sixthly, most of the studies were from China, so the conclusion might not necessarily apply in other areas. Seventhly, we only included related studies reporting OS, LNM and HTS, and the articles on other prognostic indicators were thus excluded. In the light of the above deficiencies, a more comprehensive study covering larger samples, more regions, and more indicators will be needed to confirm our results.

In conclusion, our meta-analysis found that lncRNA GAS5 could sever as a molecular biomarker to predict the prognosis of various cancers and the low GAS5 expression could indicate the poor prognosis.

**AUTHOR CONTRIBUTIONS**

QG and HX performed Data extraction, HZ and JL did the data analysis. YL and WH designed the project and QG wrote the paper. YL supervised the project. WH provided financial support for the project.

**ACKNOWLEDGMENTS**

We are very grateful to all the colleagues who had contributed to the work and were not listed on the author list. This work was supported by the National Key Basic Research Program of China (973 Program) (2014CB745201), the Chinese High-Tech (863) Program (2014AAA020607), National Natural Science Foundation of China (81402103), International S&T Cooperation program of China (ISTCP) (2014DFA31050), The National Science Foundation Projects of Guangdong Province (2014A030313717), the Shenzhen Municipal Government of China (ZDSYS2015040300172174, JCYJ20150330102721030, GJHZ20150316154912494), and Special Support Funds of Shenzhen for Introduced High-Level Medical Team.

**REFERENCES**

Batista, P. J., and Chang, H. Y. (2013). Long noncoding RNAs: cellular address codes in development and disease. Cell 152, 1298–1307. doi: 10.1016/j.cell.2013.02.012

Bian, D., Shi, W., Shao, Y., Li, P., and Song, G. (2017). Long non-coding RNA GAS5 inhibits tumorigenesis via miR-137 in melanoma. Am. J. Transl. Res. 9, 1509–1520.

Cao, Q., Wang, N., Qi, J., Gu, Z., and Shen, H. (2016). Long noncoding RNA GAS5 acts as a tumor suppressor in bladder transitional cell carcinoma via regulation of chemokine (CC motif) ligand 1 expression. Mol. Med. Rep. 13, 27–34. doi: 10.3892/mmr.2015.4503

Cao, S., Liu, W., Li, F., Zhao, W., and Qin, C. (2014). Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int. J. Clin. Exp. Pathol. 7, 6776–6783.

Chang, L., Li, C., Lan, T., Wu, L., Yuan, Y., Liu, Q., et al. (2016). Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin. Mol. Med. Rep. 13, 1541–1550. doi: 10.3892/mmr.2015.4716

Chen, Z., Xie, H., Zhong, Y., Liu, Y., and Huang, W. (2017). Role of nuclear paraseptle assembly transcript 1 as a common molecular marker for prognosis in various cancers. Minerva Med. 108, 477–479. doi: 10.23736/S0026-4806.17.05100-X

Dong, S., Qu, X., Li, W., Zhong, X., Li, P., Yang, S., et al. (2015). The long non-coding RNA GAS5 enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. J. Hematol. Oncol. 8:43. doi: 10.1186/s13045-015-0140-6

Droop, J., Sarvaz, T., Schulz, W. A., Niedworok, C., Niegisch, G., Scheckenbach, K., et al. (2017). Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma. PLoS ONE 12:e0176287. doi: 10.1371/journal.pone.0176287

Fang, L., Sun, J., Pan, Z., Song, Y., Zhong, L., Zhang, Y., et al. (2017). Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VPChkappaB. Am. J. Physiol. Gastrointest. Liver Physiol. 313:a00426.02016. doi: 10.1152/ajpgi.00426.2016

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386. doi: 10.1002/ijc.29210

Gao, J., Liu, M., Zou, Y., Mao, M., Shen, T., Zhang, C., et al. (2015). Long non-coding RNA growth arrest-specific transcript 5 is involved in ovarian cancer cell apoptosis through the mitochondria-mediated apoptosis pathway. Oncol. Rep. 34, 3212–3221. doi: 10.3892/or.2015.4318

Gee, H. E., Buffa, F. M., Camps, C., Ramachandran, A., Leek, R., Taylor, M., et al. (2011). The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br. J. Cancer 104, 1168–1177. doi: 10.1038/sj.bjc.6606076

Guo, C., Song, W. Q., Sun, P., Jin, L., and Dai, H. Y. (2015). LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J. Biomed. Sci. 22:100. doi: 10.1186/s12929-015-0213-4

Higgins, J. P., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ 327, 557–560. doi: 10.1136/bmj.327.7414.557

Huang, J. B., Thompson, A. J., Deeks, J. J., and Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ 327, 557–560. doi: 10.1136/bmj.327.7414.557

Hu, L., Ye, H., Huang, G., Luo, F., Liu, Y., Liu, Y., et al. (2016). Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tum. Biol. 37, 2691–2702. doi: 10.1007/s13277-015-4111-x

Li, J., Huang, H., Li, Y., Li, L., Hou, W., and You, Z. (2016). Decreased expression of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion, and indicates a poor prognosis in ovarian cancer. Oncol. Rep. 36, 3241–3250. doi: 10.3892/or.2016.5200

Li, T., Mo, X., Fu, L., Xiao, B., and Guo, J. (2016). Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget 7, 8601–8612. doi: 10.18632/oncotarget.6926

Li, W., Zhai, L., Wang, H., Liu, C., Zhang, J., Chen, W., et al. (2016). Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 7, 27778–27786. doi: 10.18632/oncotarget.8413

Li, Y., Li, Y., Huang, S., He, K., Zhao, M., Lin, H., et al. (2017). Long non-coding RNA growth arrest specific transcript 5 acts as a tumour suppressor in...
colorectal cancer by inhibiting interleukin-10 and vascular endothelial growth factor expression. Oncotarget 8, 13690–13702. doi: 10.18632/oncotarget.14625
Liu, Q., Liu, H., Cheng, H., Li, Y., Li, X., and Zhu, C. (2017). Downregulation of long noncoding RNA TUG1 inhibits proliferation and induces apoptosis through the TUG1/miR-142/22Erz axis in bladder cancer cells. Onc Targets Ther. 10, 2461–2471. doi: 10.2147/OTT.S124595
Liu, X., Jiao, T., Wang, Y., Su, W., Tang, Z., and Han, C. (2016). Long non-coding RNA GAS5 acts as a molecular sponge to regulate miR-23a in gastric cancer. Minerva Med. [Epub ahead of print].
Liu, Y., Zhao, J., Zhang, W., Gan, J., Hu, C., Huang, G., et al. (2015). IncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Sci. Reports 5:10159. doi: 10.1038/srep10159
Liu, Z., Wang, W., Jiang, J., Bao, E., Xu, D., Zeng, Y., et al. (2013). Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS ONE 8:e73991. doi: 10.1371/journal.pone.0073991
Luo, G., Liu, D., Huang, C., Wang, M., Xiao, Z., Xeng, F., et al. (2017). LncRNA GAS5 Inhibits Cellular Proliferation by Targeting P27Kip1. Wuhan: Molecular Cancer Research (MCR).
Ma, C., Shi, X., Zhu, Q., Li, Q., Liu, Y., Yao, Y., et al. (2016). The growth arrest-specific transcript 5 (GASS): a pivotal tumor suppressor long noncoding RNA in human cancers. Tum. Biol. 37, 1437–1444. doi: 10.1007/s13237-015-4521-9
Mattick, J. S., and Makunin, I. V. (2006). Non-coding RNA. Hum. Mol. Genet. 15, R17–R29. doi: 10.1093/hmg/ddi004
Mazar, J., Rosado, A., Shelley, J., Marchica, J., and Westmoreland, T. J. (2017). The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma. Oncotarget 8, 6589–6607. doi: 10.18632/oncotarget.14244
Mei, Y., Si, J., Wang, Y., Huang, Z., Zhu, H., Feng, S., et al. (2017). Long noncoding RNA GAS5 suppresses tumorigenesis by inhibiting miR-23a 5 expression in non-small cell lung cancer. Oncol. Res. 25, 1027–1037. doi: 10.3727/096504016X14822800040451
Pickard, M. R., and Williams, G. T. (2014). Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast Cancer Res. Treat. 145, 359–370. doi: 10.1007/s10549-014-2974-y
Pontavic, J., Ponting, C. P., and Lunter, G. (2007). Functionality or transcriptional noise? Evidence for selection within long noncoding RNAs. Genome Res. 17, 556–565. doi: 10.1101/gr.636807
Renganathan, A., Kresoja-Rakic, J., Echeverry, N., Ziltener, G., Vrutg, B., Opitz, I., et al. (2014). GAS5 long non-coding RNA in malignant pleural mesothelioma. Mol. Cancer 13:119. doi: 10.1186/1476-4598-13-119
Saika, K., and Sobue, T. (2013). [Cancer statistics in the world]. Gan to ryoho 40, 2475–2480.
Shi, X., Sun, M., Liu, H., Yao, Y., Kong, R., Chen, F., et al. (2015). A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer. Mol. Carcinogenesis 54 (Suppl. 1), E1–E12. doi: 10.1002/mc.22120
Song, W., Wang, K., Zhang, R. J., Dai, Q. X., and Zou, S. B. (2016). Long noncoding RNA GAS5 can predict metastasis and poor prognosis: a meta-analysis. Minerva Med. 107, 70–76.
Sun, M., Jin, F. Y., Xia, R., Kong, R., Li, J. H., Xu, T. P., et al. (2014). Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer 14:319. doi: 10.1186/1471-2407-14-319
Sun, Y., Zou, X., He, J., and Mao, Y. (2017). Identification of long non-coding RNAs biomarkers associated with progression of endometrial carcinoma and patient outcomes. Oncotarget. 8, 52604–52613. doi: 10.18632/oncotarget.17537
Tan, Q., Zuo, J., Qiu, S., Yu, Y., Zhou, H., Li, N., et al. (2017). Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosis/non-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker. Int. J. Oncol. 50, 1729–1738. doi: 10.3892/ijo.2017.3925
Tang, J. Y., Lee, J. C., Chang, Y. T., Hou, M. F., Huang, H. W., Liaw, C. C., et al. (2013). Long noncoding RNAs-related diseases, cancers, and drugs. ScientificWorldJournal 2013:943539. doi: 10.1155/2013/943539